Hatch, S., Swift, L., Caporali, S., Carter, R., Hill, E., Macgregor, T., . . . Sharma, R. (2014). XPF protein levels determine sensitivity of malignant melanoma cells to oxaliplatin chemotherapy: Suitability as a biomarker for patient selection.
Citación estilo ChicagoHatch, S., et al. XPF Protein Levels Determine Sensitivity of Malignant Melanoma Cells to Oxaliplatin Chemotherapy: Suitability as a Biomarker for Patient Selection. 2014.
Cita MLAHatch, S., et al. XPF Protein Levels Determine Sensitivity of Malignant Melanoma Cells to Oxaliplatin Chemotherapy: Suitability as a Biomarker for Patient Selection. 2014.
Warning: These citations may not always be 100% accurate.